US 9,808,530 B2
Composition of tiacumicin compounds
Yoshiyuki Murakami, Tokyo (JP); and Hikaru Saito, Tokyo (JP)
Assigned to Astellas Pharma Europe Ltd., Chertsey, Surrey (GB)
Appl. No. 14/766,904
Filed by Astellas Pharma Europe Ltd., Chertsey, Surrey (GB)
PCT Filed Jan. 14, 2014, PCT No. PCT/EP2014/000091
§ 371(c)(1), (2) Date Aug. 10, 2015,
PCT Pub. No. WO2014/111254, PCT Pub. Date Jul. 24, 2014.
Claims priority of application No. 13075002 (EP), filed on Jan. 15, 2013.
Prior Publication US 2016/0045603 A1, Feb. 18, 2016
Int. Cl. A61K 9/16 (2006.01); A61K 31/7034 (2006.01); A61K 31/7048 (2006.01); A61K 47/36 (2006.01); A61K 47/38 (2006.01); A61K 9/00 (2006.01); A61K 47/26 (2006.01)
CPC A61K 47/38 (2013.01) [A61K 9/0095 (2013.01); A61K 9/1652 (2013.01); A61K 31/7034 (2013.01); A61K 31/7048 (2013.01); A61K 47/26 (2013.01); A61K 47/36 (2013.01)] 10 Claims
 
1. A pharmaceutical composition comprising as the active ingredient a tiacumicin B compound, analogues thereof, a stereo-isomer thereof, a polymorph thereof or a pharmaceutically acceptable solvate thereof, and xanthan gum as an excipient, wherein the excipient is present in an amount to prevent foaming of the tiacumicin B compound in water.